Molecular Evaluation of Endometrium After Endometrial Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2020-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Repeated implantation failure (RIF) is determined when failure of implantation occurred during at least three consecutive IVF attempts while at least one high-grade embryo was transferred in each cycle. Several methods have been suggested to improve the implantation rate in RIF patients. One of the most promising methods is local injury to the endometrium. It has been reported that the rates of implantation, clinical pregnancy, and live birth reach more than double in RIF patients with local endometrial injury than patients without it. The population of this study included all infertile couples attending the Royan Institute, who have at least three consecutive cycles of ART failure. Also this study is phase 3 randomized clinical trial. Based on the average menstrual cycle 30-28 days, endometrial and blood samples were collected from two groups of patients on day 21 of luteal phase of their spontaneous menstrual cycle. The intervention, but not the control group underwent prior biopsy treatment in follicular phase on days 8 or/and 11 to 13 of that same cycle but in these days blood sample in both groups were collected. To investigate the impact of local endometrial injury in increasing the rate of pregnancy in ART - treated RIF patients, the investigators will examine the changes of immunological factors involved in the implantation including some cytokines, growth factors ( in serum and endometrial biopsies) and the expression of TLRs and HOX genes ( in endometrial biopsies) obtained from both groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Platelet Rich Plasma and Recurrent Implantation Failure

NCT03996837

Recurrent Implantation Failure

COMPLETED NA

Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure

NCT03161340

Recurrent Implantation Failure

COMPLETED PHASE2

PRP in Recurrent Implantation Failure

NCT04085783

Recurrent Implantation Failure

COMPLETED NA

Personalized FET in RIF Patients With Displaced Dating

NCT03910582

Infertility, Female

UNKNOWN NA

ERA Test in Patients With Recurrent Implantation Failure

NCT01668693

Repetitive Implantation Failure

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is phase 3 randomized clinical trial that the 20 infertile women with the following conditions will be studied in 2 groups. In the intervention group, Endometrial sampling is obtained twice by Pipelle \[one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle\]. In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Endometrial injury

In the intervention group, endometrial sampling is obtained twice by Pipelle \[one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle\]. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).

Group Type EXPERIMENTAL

PIPELLE Endometrial injury

Intervention Type PROCEDURE

The endometrial injury which is induced with pipelle.

Control

In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle. Blood samples (5- 10 cc) are taken twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PIPELLE Endometrial injury

The endometrial injury which is induced with pipelle.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \< 40 years old
* Patients had history of 3 failed consecutive cycles of IVF / ICSI.
* Patients were good responders in prior ovulation induction cycle.
* There were at least two embryos with grade A in each embryo transfer cycle.
* Normal uterus in Hysterosalpingography (HSG) or ultrasound or hysteroscopy scans.
* The minimum thickness of the endometrium is 7 mm in injection day.

Exclusion Criteria

* Submucosal myoma.
* Intramural and sub serousal myoma greater than 5 cm.
* Endometrioma equal to or greater than 3 cm or Hydrosalpinx.
* The number of available embryos is less than 2 in the current cycle.
* Patients with endometrial tuberculosis and persons who are treated for tuberculosis.
* Patients with any specific drug consumption.
* Patients with a history of thyroid disease, diabetes and other endocrine disorders.
* Lost to follow up or sampling.
* Impossibility of prepare endometrial sampling because of severe pain or probability infection.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hamid Gourabi, PhD

Role: STUDY_CHAIR

Head of Royan Institute

Reza Aflatoonian, PhD

Role: STUDY_DIRECTOR

Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.

Mahnaz Ashrafi, MD

Role: STUDY_DIRECTOR

Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.

Samaneh Aghajanpour, M.S.c

Role: PRINCIPAL_INVESTIGATOR

Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.

Elham Amirchaghmaghi, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.